Journal of Clinical Investigation · 2011 · 109 citations · 53 references
MedicineHematologyOncologyEpigeneticsGene ExpressionTranscriptional RegulationEpigenetic Regulation In CancerHematopoietic NeoplasmsHematopoietic Stem Cell BiologyMyeloid-derived Suppressor CellsMyeloproliferative NeoplasmsTumor Suppressor GenesChronic Myelomonocytic LeukemiaGene Promoter RegulationHematopoietic Lineage SpecificationHematopoietic Stem Cell Transcriptional RegulationHistone Modifications In TranscriptionMyeloid-derived Suppressor Cell Epigenetic RegulationTumor Suppressor Gene HypermethylationTumor Suppressor Loss
Transcription intermediary factor 1γ (TIF1γ) was suggested to play a role in erythropoiesis. However, how TIF1γ regulates the development of different blood cell lineages and whether TIF1γ is involved in human hematological malignancies remain to be determined. Here we have shown that TIF1γ was a tumor suppressor in mouse and human chronic myelomonocytic leukemia (CMML). Loss of Tif1g in mouse HSCs favored the expansion of the granulo-monocytic progenitor compartment. Furthermore, Tif1g deletion induced the age-dependent appearance of a cell-autonomous myeloproliferative disorder in mice that recapitulated essential characteristics of human CMML. TIF1γ was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. A demethylating agent restored the normal epigenetic status of the TIF1G promoter in human cells, which correlated with a reestablishment of TIF1γ expression. Together, these results demonstrate that TIF1G is an epigenetically regulated tumor suppressor gene in hematopoietic cells and suggest that changes in TIF1γ expression may be a biomarker of response to demethylating agents in CMML.
53
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2
Myunggon Ko, Yun Huang, A. Jankowska et al. · Nature · 2010 · 1.3K citations
Medicine, Cancer Biology, Oncology +16